Intra-Cellular Therapies (Intra-Cellular Therapies) Total Inventories

: $11.6 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Intra-Cellular Therapies's total inventories for the quarter that ended in Dec. 2023 was $11.6 Mil. Intra-Cellular Therapies's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $27.3 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Intra-Cellular Therapies's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $4.69.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Intra-Cellular Therapies's Days Inventory for the three months ended in Dec. 2023 was 232.91.

Inventory Turnover measures how fast the company turns over its inventory within a year. Intra-Cellular Therapies's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.39.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Intra-Cellular Therapies's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.21.

Intra-Cellular Therapies Total Inventories Historical Data

The historical data trend for Intra-Cellular Therapies's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

7.06

7.95

23.92

11.65

Intra-Cellular Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															23.92	28.34	41.90	42.99	11.65

Intra-Cellular Therapies Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Intra-Cellular Therapies (NAS:ITCI) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Intra-Cellular Therapies's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(497.941	+	0.75 * 114.018	+	0.5 * 11.647	-	136.871
-	0	-	0)	/	96.3798
=	4.69

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Intra-Cellular Therapies's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	27.3165	/	10.702	*	365 / 4
	=	232.91

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Intra-Cellular Therapies's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	10.702	/	27.3165
	=	0.39

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Intra-Cellular Therapies's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	27.3165	/	131.506
	=	0.21

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Intra-Cellular Therapies Total Inventories Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

ITCI:Mexico 23I:Germany 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Executives

Sharon Mates	director, officer: Chairman, President & CEO	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead	officer: SVP and General Counsel	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Suresh K. Durgam	officer: Chief Medical Officer	C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Mark Neumann	officer: EVP, Chief Commercial Officer	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline	officer: VP of Finance, CFO & Secretary	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Van Nostrand Robert L	director	C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Joel S Marcus	director	C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas	director	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs	director	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Christopher D Alafi	director, 10 percent owner	P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner	director	THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin	officer: EVP and Chief Medical Officer	C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover	officer: VP, Clinical Development	C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis	officer: SVP, Chief Scientific Officer	3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi	10 percent owner	1311 ORLEANS DRIVE, SUNNYVALE CA 94089